Josh Brumm

Josh Brumm is a seasoned executive with extensive experience in the biotechnology and life sciences sectors. Currently serving as a General Partner at Forbion and a Board Member at AIRNA, Josh also holds the position of Chairman of the Board at Amphista Therapeutics Limited. Previously, Josh was President and CEO of Dyne Therapeutics, and held key leadership roles at Kaleido Biosciences, Aravive, Inc., and Pharmacyclics, where contributions included successful public offerings and strategic operational initiatives. Josh's professional journey includes a robust background in finance, operations, and corporate governance, underpinned by an education in Business Administration, Finance, and Economics from the University of Notre Dame.